© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
May 25, 2021
Experts in SMA provide closing thoughts on unmet needs in SMA including the importance of research into treatment combinations and sequencing as well as multidisciplinary care and healthcare equity.
May 20, 2021
Emma Ciafaloni, MD and Mary Schroth, MD, FAAP, FCCP consider the importance of shared decision making for patients and families when selecting an available DMT in SMA.
May 18, 2021
Kevin U. Stephens, Sr., MD, JD and Maria Lopes, MD, MS provide insight into the factors that payors must consider when creating and implementing policies on treatment coverage in SMA.
May 13, 2021
Emma Ciafaloni, MD and Mary Schroth, MD, FAAP, FCCP discuss recent clinical trial designs and results for new disease-modifying treatments in SMA: onasemnogene and risdiplam.
May 11, 2021
Emma Ciafaloni, MD and a panel of experts in SMA review the efficacy of nusinersen by discussing difference between clinical trial results and real-world clinical application.
May 06, 2021
A multidisciplinary panel of experts discusses the rapid pace of advancements in disease-modifying treatments and shares insights into how to work with payors to adapt and improve policies.
May 04, 2021
Panelists provide insight into current challenges with payor models and early screening for SMA and discuss the importance of partnering with payors when rapid diagnosis and treatment are required.
April 29, 2021
Experts in the management of SMA discuss the screening and diagnosis of infants, children, and adult patients and emphasize the importance of health care equity to avoid treatment delay.
April 27, 2021
Key opinion leaders in SMA emphasize the importance of a multidisciplinary approach and centers of excellence in the early diagnosis and treatment of spinal muscular atrophy.
April 22, 2021
A multidisciplinary panel of experts discusses the clinical burden of spinal muscular atrophy on patients, families, and caregivers and considers the importance of patient education and advocacy.